drugset / Trial / NCT07583953
An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors
Phase 0
Not yet recruiting
50 enrolled
Suzhou Abogen Biosciences Co., Ltd.
The First Affiliated Hospital of Soochow University · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of ABO2109 in combination with toripalimab, and to evaluate the immunogenicity, pharmacokinetics, pharmacodynamics, as well as biomarker characteristics of the investigational cancer vaccine. In addition, the antitumor activity of ABO2109 will be assessed during both dose exploration and expansion stages, the accumulative data will support the clinical development of ABO2109.
Timeline
- Start
- 2026-04-17
- Primary completion
- 2029-01-31
- Completion
- 2031-04-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABO2109 | Vaccine | — | Intramuscular |
| Subject | Toripalimab | Monoclonal antibody | — | Intravenous |